Comparative Efficacy of Metformin and Liraglutide in Pediatric Type 2 Diabetes

Objective:  To assess the safety and efficacy of liraglutide versus metformin in patients with type 2 diabetes in the pediatric age group Methods: This was an open-label, 24-week randomized controlled experiment. Three to sixteen-year-old Children with type 2 diabetes were randomized to receive either metformin or liraglutide. The main outcome was the variation in HbA1c at week 24. The research was completed by 150 subjects in all, and analysis was done on this cohort. Results: At week 24, the metformin group had a decrease in HbA1c (p value = 0.001), going from 8.0 ± 0.7% to 7.2 ± 0.8% (53 ± 2 mmol/mol), and in the liraglutide group (p = 0.001), going from 7.7 ± 0.7% to 7.1 ± 0.6% (52 ± 2 mmol/mol). However, the group comprised liraglutide grasped maximum decline more quickly as compared to metformin group. The incidence of hypoglycemia and other parameters studied did not differ significantly across the groups. Conclusion: During a 24-week period, individuals with T2DM treated with liraglutide and metformin alone had comparable reductions in HbA1c, with no discernible differences in other metrics.